利妥昔单抗应用于原发性膜性肾病的研究进展

被引：4

作者：

张英楠

涂阳科

机构：

[1] 天津中医药大学研究生院

来源：

中国新药与临床杂志 | 2016年 / 35卷 / 05期

关键词：

利妥昔单抗; 肾小球肾炎,膜性; 治疗效果; 安全;

D O I：

10.14109/j.cnki.xyylc.2016.05.001

中图分类号：

R692 [肾疾病];

学科分类号：

摘要：

利妥昔单抗是针对B细胞表面抗原CD20的单克隆抗体,可选择性杀伤B细胞,减少循环抗体的产生及机体免疫反应,进而达到治疗原发性膜性肾病（IMN）的目的。目前研究发现利妥昔单抗治疗IMN有较好的疗效及安全性,初始治疗方案主要有三种,即4剂疗法、2剂疗法与单剂疗法,维持治疗方案有以B细胞为指标的治疗及固定时间间隔后重复治疗。利妥昔单抗治疗IMN期间应监测B细胞数量、CD4+ T细胞与CD8+ T细胞比值、抗磷脂酶A2受体抗体滴度等,人抗嵌合体抗体对再治疗的影响尚不完全明确。两项与利妥昔单抗治疗IMN相关的多中心研究正在进行中,将为IMN的治疗提供更为科学的依据。

引用

页码：305 / 310

页数：6

共 9 条

[1]

Pathophysiological advances in membranous nephropathy: time for a shift in patient's care [J] . Pierre Ronco,Hanna Debiec.&nbsp&nbspThe Lancet . 2015 (9981)

[2] Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease [J].

Buelli, Simona ;

Perico, Luca ;

Galbusera, Miriam ;

Abbate, Mauro ;

Morigi, Marina ;

Novelli, Rubina ;

Gagliardini, Elena ;

Tentori, Chiara ;

Rottoli, Daniela ;

Sabadini, Ettore ;

Saito, Takao ;

Kawano, Mitsuhiro ;

Saeki, Takako ;

Zoja, Carlamaria ;

Remuzzi, Giuseppe ;

Benigni, Ariela .

EBIOMEDICINE, 2015, 2 (05) :456-466

[3] Long-Term Prognosis of Adult Patients with Steroid-Dependent Minimal Change Nephrotic Syndrome Following Rituximab Treatment [J].

Iwabuchi, Yuko ;

Takei, Takashi ;

Moriyama, Takahito ;

Itabashi, Mitsuyo ;

Nitta, Kosaku .

MEDICINE, 2014, 93 (29) :e300

[4]

Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial [J] . Andrew Howman,Tracey L Chapman,Maria M Langdon,Caroline Ferguson,Dwomoa Adu,John Feehally,Gillian J Gaskin,David RW Jayne,Donal O’Donoghue,Michael Boulton-Jones,Peter W Mathieson.&nbsp&nbspThe Lancet . 2013 (9868)

[5] Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature [J].

Kong, Wai Yew ;

Swaminathan, Ramyasuda ;

Irish, Ashley .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2013, 45 (03) :795-802

[6]

Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab [J] . Marco Ladino,David Roth.&nbsp&nbspNDT Plus . 2009 (5)

[7]

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases [J] . Vincent Guigonis,Aymeric Dallocchio,Véronique Baudouin,Maud Dehennault,Caroline Hachon-Le Camus,Mickael Afanetti,Jaap Groothoff,Brigitte Llanas,Patrick Niaudet,Hubert Nivet,Natacha Raynaud,Sophie Taque,Pierre Ronco,Fran?ois Bouissou.&nbsp&nbspPediatric Nephrology . 2008 (8)

[8] Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient [J].

Gallon, L. ;

Chhabra, D. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (12) :3017-3021

[9] Rituximab for idiopathic membranous nephropathy [J].

Remuzzi, G ;

Chiurchiu, C ;

Abbate, M ;

Brusegan, V ;

Bontempelli, M ;

Ruggenenti, P .

LANCET, 2002, 360 (9337) :923-924

← 1 →